Related Experiment Video
Updated: Jun 12, 2026

A Murine Model of Stent Implantation in the Carotid Artery for the Study of Restenosis
Published on: May 14, 2013
Stent Thrombosis: A Narrative Review From Pathophysiology to Therapy
Emanuele Cecchi1, Andrea Grasso Granchietti1,2, Ruggero Mazzotta2
1Department of Clinical and Experimental Medicine, University of Florence, School of Human and Health Science, Florence, Italy.
Insights
Stent thrombosis (ST) is a serious complication of percutaneous coronary intervention (PCI). Understanding its causes and optimizing treatment, including dual antiplatelet therapy, is crucial for prevention and improved patient outcomes.
Area of Science:
- Cardiology
- Interventional Cardiology
- Biomedical Engineering
Background:
- Stent thrombosis (ST) is a rare but critical complication following percutaneous coronary intervention (PCI).
- Despite technological advancements, ST presents significant challenges due to its complex pathophysiology and management.
- High rates of myocardial infarction and mortality are associated with ST.
Purpose of the Study:
- To review the current literature on stent thrombosis.
- To explore pathophysiological mechanisms, clinical predictors, and management strategies for ST.
- To highlight emerging therapeutic and preventive approaches for ST.
Main Methods:
- Conducted a narrative literature review.
- Focused on stent-related, pharmacological, and patient-related factors.
- Examined contemporary management, emerging therapies, and preventive strategies for ST.
Main Results:
- ST results from mechanical issues (malapposition, neoatherosclerosis), pharmacological factors (inadequate dual antiplatelet therapy), and patient conditions (hypercoagulability, inflammation).
- Prompt PCI and intravascular imaging are key for acute ST management.
- Newer stents and imaging-guided PCI reduce ST, with promising adjunctive therapies under investigation.
Conclusions:
- ST necessitates an integrated approach combining optimized PCI, tailored antithrombotic therapy, and risk stratification.
- Advances in device technology, pharmacology, and understanding inflammation are expected to improve ST prevention and outcomes.
Background:
Stent thrombosis (ST) remains a rare but potentially life-threatening complication of percutaneous coronary intervention (PCI), associated with high rates of myocardial infarction and mortality. Despite advances in stent technology and antithrombotic therapy, its multifactorial pathophysiology and optimal management remain challenging.
Methods:
We performed a narrative review of the current literature focusing on the pathophysiological mechanisms, clinical predictors, and contemporary management strategies of ST. Particular attention was given to stent-related, pharmacological, and patient-related factors, as well as emerging therapeutic approaches and preventive strategies.
Results:
ST arises from the complex interplay between mechanical factors (e.g., stent malapposition, underexpansion, and neoatherosclerosis), pharmacological aspects (e.g., premature discontinuation or inadequate response to dual antiplatelet therapy), and patient-related conditions, including hypercoagulability and systemic inflammation. In the acute setting, prompt PCI with restoration of coronary flow remains the cornerstone of treatment, while intravascular imaging plays a key role in identifying underlying mechanisms and optimizing outcomes. Preventive strategies rely on procedural optimization, appropriate antithrombotic therapy, and careful patient selection. New-generation drug-eluting stents and imaging-guided PCI have reduced ST incidence, whereas emerging approaches-including drug-coated balloons, subcutaneous antiplatelet agents, and anti-inflammatory therapies-represent promising adjunctive strategies, although ST-specific benefits are not yet fully established.
Conclusions:
ST is a multifactorial complication requiring an integrated approach combining optimized PCI techniques, tailored antithrombotic therapy, and careful risk stratification. Ongoing advances in device technology and pharmacological treatments, along with a growing understanding of inflammatory pathways, may further improve prevention and clinical outcomes.
More Related Videos
09:19In Vitro Microfluidic Disease Model to Study Whole Blood-Endothelial Interactions and Blood Clot Dynamics in Real-Time
Published on: May 24, 2020
05:44Author Spotlight: Utilizing Venoplasty Balloon Model in Rodents to Simulate Surgical Interventions for Deep Veins
Published on: May 24, 2024
Related Concept Videos
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Atherosclerosis III: Management
Peripheral Artery Disease III: Interprofessional Care
Venous Thrombosis I: Introduction
Venous Thrombosis III: Interprofessional Care